Deuremidevir hydrobromide treatment for RSV in infants and young children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled, parallel-group Phase III trial plans to enroll about 498 infants and young children aged 1 to 36 months with confirmed RSV infection and symptom duration ≤96 hours. Participants are randomized 2:1 to receive weight-based deuremidevir hydrobromide (20 mg/kg) or matching placebo three times daily for five consecutive days (15 doses). Eligibility requires tachypnea, wheezing, and a Wang Bronchiolitis Score ≥5, and clinical signs and safety outcomes will be monitored during treatment and follow-up. The trial is being conducted at pediatric hospitals in Xiamen, Changsha, and Chengdu, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Infants and young children aged ≥ 1 month and ≤ 36 months, regardless of gender;
2. Weight ≥ 2.5 kg and ≤ 20 kg;
3. Positive RSV antigen or nucleic acid test
4. Duration of illness due to RSV infection ≤ 96 hours;
5. Presence of tachypnea and wheezing;
6. Wang Bronchiolitis Score≥ 5;
7. For subjects aged \< 12 months, head circumference should be within the normal range corresponding to their age and gender.

Exclusion Criteria:

1. Subjects who have received protocol-specified prohibited medications:
2. Subjects with severe intrapulmonary complications or extrapulmonary complications;
3. Subjects requiring vasopressors or inotropic agents;
4. Subjects with known concurrent SARS-CoV-2 infection, influenza virus infection, Mycoplasma infection, or suspected concurrent bacterial or other pathogen infections;
5. Subjects with a known history of hypercapnia;
6. Subjects with chronic or persistent feeding difficulties;
7. Subjects with gastrointestinal diseases that the investigator believes may significantly affect the absorption of the study drug;
8. Subjects with congenital metabolic abnormalities;
9. Subjects with bronchopulmonary dysplasia requiring assisted ventilation or clinically significant congenital respiratory tract abnormalities;
10. Subjects with congenital heart disease (CHD) that the investigator assesses may affect efficacy evaluation;
11. Subjects with clinical evidence of hepatic decompensation; or abnormal liver function tests;
12. Subjects with renal failure, including renal abnormalities potentially related to renal insufficiency or abnormal renal function tests;
13. Subjects with a known history of HIV positivity, or suspected to be HIV positive by the investigator;
14. Subjects with known or suspected primary immunodeficiency diseases or transplant recipients;
15. Subjects with a history of epilepsy or febrile convulsions;
16. Subjects with a personal or family history of severe allergies or allergies;
17. Subjects with active or uncontrolled respiratory, cardiac, hepatic, central nervous system, or renal diseases, or other medical conditions deemed unsuitable for enrollment by the investigator;
18. Subjects who participated in other drug or medical device clinical trials and received investigational products or devices;
19. Subjects deemed unsuitable for participation in this study by the investigator for any other reason.

Where it's running

• The First Affiliated Hospital Of Xiamen University
  Xiamen, Fujian, China Recruiting
• Hunan Children's Hospital
  Changsha, Hunan, China Recruiting
• West China Second University Hospital Sichuan University
  Chengdu, Sichuan, China Not yet recruiting
• Shulan(hangzhou)Hospital
  Hangzhou, Zhejiang, China Not yet recruiting

Study contacts

• Principal investigator: hanmin liu — West China Second University Hospital
• Study coordinator: zhibiao song
• Email: songzhibiao@simcere.com
• Phone: 86-13641133681

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RSV strains and illness burden in Vietnamese adults aged 60 and older

  This project will test how common RSV is and which strains and severity patterns occur in people aged 60+ who are hospitalized with acute respiratory illness or worsening heart/lung disease.

  Recruiting Tam Anh Research Institute · Ho Chi Minh City, Southern Vietnam · NCT07239583

• Remdesivir for RSV in immunocompromised adults

  This trial tests whether a short course of intravenous remdesivir can help adults whose immune systems are weakened by cellular or bispecific antibody therapies recover from upper respiratory RSV infection.

  Recruiting at 3 sites Phase 2 Fred Hutchinson Cancer Center · Duarte, California and 2 other locations · NCT06817889

• rBCG-N-RSV vaccine test in adults 60+ compared with standard BCG

  This phase 2 study tests whether the rBCG-N-RSV vaccine is safe in adults over 60 and how its immune effects compare to conventional BCG.

  Recruiting Phase 2 Biothervax SpA · Athens · NCT07762014

• Nasal immune responses in older adults with pneumococcal or viral respiratory infections

  This project will test whether nasal immune responses differ in adults 60–85 with pneumococcal pneumonia, older adults carrying pneumococcus without symptoms, and those with flu or RSV.

  Recruiting University Hospital, Geneva · Geneva · NCT06998251

• RSV vaccine safety and immune response in lung transplant patients vs. healthy adults

  This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.

  Recruiting Phase 4 Seoul National University Hospital · Seoul, Jongno-Gu · NCT07895394

• RSV vaccine in children at high risk to see if it is safe and makes a strong immune response

  This study tests whether the RSVpreF vaccine is safe and helps the immune system in children aged 5 to under 18 who are at high risk for RSV illness, including those who are immunocompromised.

  Recruiting at 11 sites Phase 3 Pfizer · Durham, North Carolina and 19 other locations · NCT07839871

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.